Stock futures slipped Tuesday morning amid lingering uncertainty about the Federal Reserve’s future interest rate moves and concerns over high valuations in the technology sector.
Here are some of Tuesday’s biggest stock movers:
Biggest stock gainers
-
Hims & Hers Health (HIMS) +6% – Shares rose after the company delivered mixed Q3 results and tightened its full-year adjusted EBITDA outlook. Revenue rose 49% Y/Y to ~$599M, with monthly online revenue per average subscriber increasing to $80 from $67. Subscriber count climbed 21% to ~2.5M. The company now expects 2025 adjusted EBITDA of $307M–$317M (from $295M–$335M) and narrowed its revenue guidance to $2.335B–$2.355B vs. a prior $2.3B–$2.4B range (consensus: $2.34B). Hims & Hers also said it’s in discussions with Novo Nordisk (NVO) to offer the weight-loss drug Wegovy on its platform.
Biggest stock losers
- Sarepta Therapeutics (SRPT) -37% – Shares tumbled after its late-stage trial evaluating exon-skipping gene therapies AMONDYS 45 and VYONDYS 53 for Duchenne muscular dystrophy failed to meet its primary endpoint in a 225-patient study involving boys aged 6–13. The company noted the nine-year trial faced challenges from the COVID-19 pandemic, though the therapies continued to show a stable long-term safety profile. Sarepta also posted Q3 results, with revenue of $399.4M, down 14.5% Y/Y but ahead of expectations.
- Hive Blockchain Technologies (HIVE) -6% – Crypto-related stocks dropped sharply after Bitcoin slid as much as 2.7%, falling to $103,744, its lowest level in over two weeks. This decline follows a major liquidation event three weeks ago that erased billions in leveraged crypto positions, contributing to ongoing market volatility and investor caution in the digital asset space. Notable U.S. crypto-related names including Riot Blockchain (RIOT), Marathon Digital Holdings (MARA), MicroStrategy (MSTR), Coinbase Global (COIN), Bitfarms Ltd. (BITF), and Robinhood Markets (HOOD) all saw declines in their stock prices between 3% and 5%.
- Palantir (PLTR) -4% – Shares dipped even after posting strong Q3 results and raising full-year guidance. Revenue jumped 63% Y/Y to $1.18B, driven by a 77% surge in U.S. revenue, including 121% growth in U.S. commercial and 52% growth in U.S. government segments. The company closed 204 deals worth $1M+, totaling $2.76B in contract value, while customer count rose 45% Y/Y. Palantir guided Q4 revenue above expectations at $1.327B–$1.331B and lifted its full-year revenue outlook to $4.396B–$4.4B, with higher operating profit and free cash flow forecasts.